Resistance is futile with fourth-generation EGFR inhibitors

Nat Cancer. 2022 Apr;3(4):381-383. doi: 10.1038/s43018-022-00365-2.
No abstract available

Publication types

  • Comment

MeSH terms

  • Carcinoma, Non-Small-Cell Lung*
  • ErbB Receptors / genetics
  • Humans
  • Lung Neoplasms*

Substances

  • EGFR protein, human
  • ErbB Receptors